RecruitingNot ApplicableNCT07363551

Omega-3 Fatty Acids, Inflammation, Gut Microbiota in Youth With Depression

Omega-3 Fatty Acids, Inflammation, Gut Microbiota in Youth With Depression (OMIMYDep)- A Double-blind Randomized Controlled Trial


Sponsor

China Medical University Hospital

Enrollment

60 participants

Start Date

Jun 9, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This is a 12 week double blind RCT aimed to investigate the role of omega-3 fatty acids in patients with major depressive disorder


Eligibility

Min Age: 13 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether omega-3 fatty acid supplements (like fish oil) can reduce inflammation, improve mood, and support healthy gut bacteria in young people diagnosed with a major depressive episode (MDE). **You may be eligible if...** - You are a young person with a diagnosed major depressive episode (MDE) according to standard psychiatric criteria **You may NOT be eligible if...** - You have changed your antidepressant medication or started/stopped therapy within the past 4 weeks - You are allergic to omega-3 fatty acids (found in fish oil) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTOmega-3 fatty acids

omega-3 fatty acids (EPA)

DIETARY_SUPPLEMENTPlacebo

soy bean oil


Locations(1)

China Medical University

Taichung, Taichung, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07363551


Related Trials